NovaBridge Biosciences Stock
NovaBridge Biosciences
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Srishti Gupta
- Employees
- 30
- Market cap
- $145 M
- IPO
- 17/01/2020
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer;…
NovaBridge Biosciences stock: price history
1D
-2.3%
1W
-10.0%
1M
-19.7%
6M
-53.3%
YTD
-68.3%
1Y
-80.8%
2Y
-6.7%
5Y
-98.1%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~0% stronger price swings than usual
Ask the agents about NovaBridge Biosciences
Analyst assessment of NovaBridge Biosciences
PRICE TARGET LOW
US$7.00
CONSENSUS
US$8.25
MEDIAN
US$8.50
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
11
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 20/08/2026
NovaBridge Biosciences stock metrics
P/E
-2.21
P/B
0.73
EV/EBITDA
0.74
RETURN ON EQUITY
-9.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.8%
FLOAT SHARES
41,971,997
AVG. DAILY VOLUME (30D)
532,065
Insider transactions (SEC)
Dennis Phillip Andrew
Dennis Phillip Andrew
Cao Sean Wuxiong
Cao Sean Wuxiong
Cao Sean Wuxiong
Comparable stocks
Frequently asked questions about NovaBridge Biosciences stock
What does NovaBridge Biosciences do?
NovaBridge Biosciences is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Srishti Gupta, the company employs around 30 people.
The IPO was on 17/01/2020; the stock trades on NASDAQ under the ticker NBP.
What do analysts say about NovaBridge Biosciences stock?
11 analysts rate the stock, the consensus is Buy (as of 20/08/2026).
The average price target is US$8.25, ranging from US$7.00 to US$9.00, with a median of US$8.50.
This is an external assessment, not a statement by Market Jury.
When does NovaBridge Biosciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does NovaBridge Biosciences pay a dividend?
No, NovaBridge Biosciences currently does not pay a dividend.
Which stocks are comparable to NovaBridge Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get NovaBridge Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess NovaBridge Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.